# A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

> **NCT04640077** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 95 (actual)

## Conditions studied

- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Cognitive Impairment

## Interventions

- **OTHER:** No Intervention
- **DRUG:** donanemab

## Key facts

- **NCT ID:** NCT04640077
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-23
- **Primary completion:** 2024-02-27
- **Final completion:** 2024-02-27
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640077, "A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04640077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*